 Connection
William Robinson to Drug Administration Schedule
This is a "connection" page, showing publications William Robinson has written about Drug Administration Schedule.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.032 |
|
|
|
-
Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94.
Score: 0.016
-
Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol. 1995 Dec; 18(6):488-90.
Score: 0.007
-
Feun LG, Gonzalez R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar; 9(3):464-7.
Score: 0.005
-
Gordon GS, Ambruso DR, Robinson WA, Githens JH. Intranasal administration of deferoxamine to iron overloaded patients. Am J Med Sci. 1989 May; 297(5):280-4.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|